Neurocrine Biosciences has recently announced that its pipeline asset, Ingrezza (valbenazine), achieved the primary endpoint of reducing the symptoms of chorea (involuntary muscle movements) associated with Huntington’s disease (HD) in the Phase III clinical trial, KINECT-HD (NCT04102579). This will propel Ingrezza into a dominant position in the HD market, due to its convenient once-daily dosing…
UCB announces positive Phase 3 results for rozanolixizumab in generalised myasthenia gravis
Positive topline results from UCB MycarinG study investigating the efficacy and safety of rozanolixizumab in patients with generalised myasthenia gravis (gMG) Study met primary and all secondary endpoints with statistical significance Rozanolixizumab was well tolerated with no new observed safety signals UCB plans regulatory submissions for rozanolixizumab in gMG from Q3 2022 December 10th, 2021…
ACNR indexed in DOAJ (Directory of Open Access Journals)
DOAJ indexes and promotes quality, peer-reviewed open access journals from around the world. It is the most important community-driven, open access service in the world and has a reputation for advocating best practices and standards in open access. DOAJ’s basic criteria for inclusion have become the accepted way of measuring an open access journal’s adherence to standards…
WFNR celebrates 25th anniversary
“Congratulations to the WFNR for all that it has achieved over the last 25 years. Today the WFNR is a true advocate for neurorehabilitation” said Professor David Good, WFNR President as the organisation celebrates its 25th anniversary. He continued: “We’re extremely grateful to all our members who have contributed to the success of the organisation…
Apomorphine Sublingual Film for PD
BIAL announced on 2nd September 2021 that it has entered into an agreement with Sunovion Pharmaceuticals Inc. (Sunovion) whereby BIAL received exclusive commercial license rights to commercialise apomorphine sublingual film in the European Union (EU), the European Economic Area (EEA) and the United Kingdom. Apomorphine sublingual film (APL-130277) is a novel thin film formulation of…
New support group for families affected by brain injury
A new Special Interest Group (SIG) was launched on September 9, 2021 to provide support, advice and resources to families affected by acquired brain injury (ABI). Anchor Point will raise awareness of the needs of families of people with a brain injury, identify their unmet needs and deliver research, information and education required to make…
Ratlas: A new rat brain atlas set to revolutionise neuroscience
The BNA has announced the launch of Ratlas, a new – and freely available – resource that will increase the accuracy and efficiency of experiments and also help to reduce animal numbers used for neuroscience research across the UK. Ratlas is an atlas of the rat brain that has been developed to revolutionise and support vital…
The Mike Barnes Award for Innovation 2021
Calling all change makers! The Mike Barnes Award for Innovation 2021 recognises and celebrates innovative projects and concepts in the management of Acquired Brain Injury (ABI). It is open to people who may have a project to look at new ways of improving an aspect of neurorehabilitation in hospital, the community, school or prison. You…
MHRA approves PONVORY® (ponesimod) for the Treatment of Adults with Relapsing Forms of Multiple Sclerosis (RMS)
The Janssen Pharmaceutical Companies of Johnson & Johnson announced on August 10th 2021 that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted Marketing Authorisation in Great Britain for PONVORY® (ponesimod) for the treatment of adult patients with relapsing multiple sclerosis (RMS) with active disease defined by clinical or imaging features.2-4 “We are delighted…
